The recommendation, which makes Cosentyx the first biologic treatment for HS since 2016, specifically applies to patients who have had an inadequate response to conventional systemic HS therapy and where adalimumab is not suitable, did not work or has stopped working.
At least 200,000 people in the UK are affected by HS, a chronic and progressive inflammatory skin disease that causes boil-like abscesses that can burst, creating open wounds and irreversible scarring…
